{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-090722","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.350954+00:00","generated_at":"2026-05-31T12:59:01.263194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enanta reports Q3 net loss $22.7M, cash $272.6M; RSV trials on track","bullets":["Revenue $18.0M (royalty from AbbVie's MAVYRET); net loss $22.7M ($1.07 EPS) vs $39.1M loss a year ago.","Cash, equivalents and securities $272.6M at June 30, 2024; expects runway through Q3 FY2027.","Completed enrollment in RSVPEDs Phase 2 study of zelicapavir in pediatric RSV; topline data expected Q4 2024.","EDP-323 Phase 2a challenge study completed; topline data expected late Q3 2024.","Legal expenses increased due to patent infringement lawsuit against Pfizer; no Q3 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-090722","json":"https://secwatch.observer/filing/0000950170-24-090722.json","markdown":"https://secwatch.observer/filing/0000950170-24-090722.md","text":"https://secwatch.observer/filing/0000950170-24-090722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024090722/0000950170-24-090722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024090722/enta-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:59:01.263194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}